Phuturdex › Diseases › Graft-versus-host disease
Drugs in development · updated 30 October 2026
Graft-versus-host disease: drugs in development
As of 30 October 2026 there are 56 active clinical trials (recruiting or ongoing, phases I–III) on 49 drugs for graft-versus-host disease. 10 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Rovadicitinib | III | 1 | NCT06682169 |
| BPC-2001 | II | 1 | NCT07246031 |
| BPX-501 | I–II | 1 | NCT01744223 |
| CK0802 | I–II | 1 | NCT07576699 |
| Granulocytes | I–II | 1 | NCT00900497 |
| IvarmacitinibSHR0302 | II | 1 | NCT07570745 |
| Madecassoside Tablets | II | 1 | NCT07606703 |
| RimiducidAP1903 | I–II | 1 | NCT01744223 |
| Withaferin A | II | 1 | NCT07708987 |
| TRX103 | I | 1 | NCT06462365 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II–III | 28 | NCT07297914 |
| Mycophenolate MofetilMycophenolate, Cellcept | III | 12 | NCT06615050 |
| TacrolimusEnvarsus XR, Prograf® | III | 10 | NCT06615050 |
| RuxolitinibJakavi, Jakafi Xr® | III | 9 | NCT06615050 |
| MethotrexateJylamvo®, Reditrex® | III | 6 | NCT06615050 |
| BaricitinibOlumiant® | II–III | 1 | NCT06475820 |
| BlinatumomabBlincyto® | II–III | 1 | NCT07297914 |
| ImatinibSTI571, Imkeldi® | III | 1 | NCT06682169 |
| RituximabRuxience, Rituxan | III | 1 | NCT06682169 |
| FludarabineFludara, FLUDARABIN | I–II | 12 | NCT06434363 |
| SirolimusRapamycin, Scomara® | I–II | 9 | NCT07796620 |
| BusulfanBusulphan, Busulfex® | I–II | 8 | NCT03597594 |
| AbataceptOrencia® | I–II | 6 | NCT05289167 |
| MelphalanEvomela®, Hepzato® | I–II | 6 | NCT03192397 |
| ThiotepaTepylute®, Tepadina And Sodium Chloride® | I–II | 5 | NCT03597594 |
Sorted by most advanced phase and number of active trials. Showing 15 of 39 drugs.
All 49 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Bronchiolitis obliterans syndrome 36 drugs
- Hematologic neoplasm 216 drugs
- Bronchiolitis obliterans 6 drugs
- Lung disease 104 drugs
- Chronic lymphocytic leukemia 137 drugs
- Mantle cell lymphoma 108 drugs
- Follicular lymphoma 144 drugs
- Diffuse large B-cell lymphoma 177 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Bronchial disease 4 drugs
Broader categories
- Immune System Diseases 54 drugs
- Hematologic Diseases 57 drugs
- Neoplasm 671 drugs
- Bone marrow disease 14 drugs
- Myeloid leukemia 26 drugs
- Leukemia 153 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006086 “Graft vs Host Disease”. Prevalence: Orphanet.